Safety and Efficacy Study of Thymoglobulin Versus IL2 Receptor Antagonists
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and efficacy of induction therapy with
Thymoglobulin in comparison with IL2 receptor antagonists (daclizumab or basiliximab).
Phase:
N/A
Details
Lead Sponsor:
Medical University of South Carolina
Collaborator:
Genzyme, a Sanofi Company
Treatments:
Antilymphocyte Serum Daclizumab Immunoglobulin G Thymoglobulin